MNOV stock forecast
Our latest prediction for MediciNova, Inc.'s stock price was made on the March 12, 2020 when the stock price was at 3.13$.
In the short term (2weeks), MNOV's stock price should outperform the market by 5.96%. During that period the price should oscillate between -10.37% and +27.81%.
In the medium term (3months), MNOV's stock price should outperform the market by 8.36%. During that period the price should oscillate between -30.61% and +58.63%.Get email alerts
Create a solid portfolio with MNOV
About MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
At the moment the company generates 6M USD in revenues.
On its last earning announcement, the company reported a loss of -0.30$ per share.
The book value per share is 1.80$
Three months stock forecastMarch 12, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|